{"data":[{"accessionNo":"0001493152-26-047551","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":"501976104","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-30","reportingPerson":"AIGH Capital Management LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":3650000,"percentOfClass":5.9,"filedAt":"2026-10-19","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001493152-26-047551","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":"501976104","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-30","reportingPerson":"Orin Hirschman","reportingCik":null,"personType":"HC,IN","sharesOwned":3650000,"percentOfClass":5.9,"filedAt":"2026-10-19","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001193125-26-350332","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001994702","issuerName":"KYVERNA THERAPEUTICS, INC.","ticker":"KYTX","cusip":"501976104","securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2026-06-30","reportingPerson":"Bain Capital Life Sciences Opportunities III, LP","reportingCik":null,"personType":"PN","sharesOwned":2885000,"percentOfClass":4.75,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0002012383-26-002893","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001994702","issuerName":"KYVERNA THERAPEUTICS INC","ticker":"KYTX","cusip":"501976104","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":3103757,"percentOfClass":5.1,"filedAt":"2026-07-29","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001972690-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Michael P. Rubin","reportingCik":null,"personType":"IN","sharesOwned":3466826,"percentOfClass":6.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001193125-26-054806","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"KYVERNA THERAPEUTICS, INC.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-12-31","reportingPerson":"Bain Capital Life Sciences Opportunities III, LP","reportingCik":null,"personType":"PN","sharesOwned":3110000,"percentOfClass":5.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001972690-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Northpond Ventures III, LP","reportingCik":null,"personType":"PN","sharesOwned":2805426,"percentOfClass":4.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001972690-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Northpond Ventures III GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":2805426,"percentOfClass":4.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001972690-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Northpond Ventures GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":450000,"percentOfClass":0.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001972690-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Northpond Ventures, LP","reportingCik":null,"personType":"PN","sharesOwned":450000,"percentOfClass":0.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001972690-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"NPV Listed, LLC","reportingCik":null,"personType":"OO","sharesOwned":211400,"percentOfClass":0.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001972690-26-000003","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Northpond Ventures, LLC","reportingCik":null,"personType":"OO","sharesOwned":211400,"percentOfClass":0.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001104659-26-011469","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Dr. Beth C. Seidenberg (\"Seidenberg\")","reportingCik":null,"personType":"IN","sharesOwned":4657257,"percentOfClass":7.8,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001104659-26-011469","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Westlake BioPartners GP I, LLC (\"Westlake GP I\")","reportingCik":null,"personType":"OO","sharesOwned":3787940,"percentOfClass":6.3,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001104659-26-011469","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Westlake BioPartners Fund I, L.P. (\"Westlake Fund I\")","reportingCik":null,"personType":"PN","sharesOwned":3787940,"percentOfClass":6.3,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001104659-26-011469","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\")","reportingCik":null,"personType":"OO","sharesOwned":869317,"percentOfClass":1.5,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0001104659-26-011469","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity Fund I\")","reportingCik":null,"personType":"PN","sharesOwned":869317,"percentOfClass":1.5,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0000919574-25-007080","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-11-13","reportingPerson":"Craig D. Gordon","reportingCik":null,"personType":"HC,IN","sharesOwned":3058485,"percentOfClass":7,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0000919574-25-007080","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-11-13","reportingPerson":"GordonMD Global Investments GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":3058485,"percentOfClass":7,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0000919574-25-007080","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-11-13","reportingPerson":"GordonMD Global Investments LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3058485,"percentOfClass":7,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0000919574-25-007080","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-11-13","reportingPerson":"GordonMD Long Biased Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":2735783,"percentOfClass":6.2,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"},{"accessionNo":"0000919574-25-007080","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001994702","issuerName":"Kyverna Therapeutics, Inc.","ticker":"KYTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-11-13","reportingPerson":"GordonMD Long Biased GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2735783,"percentOfClass":6.2,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/kytx"}],"updatedAt":"2026-11-05T00:24:30.782Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/kytx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}